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Although Duchenne muscular dystrophy is primarily classiﬁed as a neuromuscular disease, cardiac complications play an
important role in the course of this X-linked inherited disorder. The pathobiochemical steps causing a progressive decline in
the dystrophic heart are not well understood. We therefore carried out a ﬂuorescence diﬀerence in-gel electrophoretic analysis
of 9-month-old dystrophin-deﬁcient versus age-matched normal heart, using the established MDX mouse model of muscular
dystrophy-related cardiomyopathy. Out of 2,509 detectable protein spots, 79 2D-spots showed a drastic diﬀerential expression
pattern, with the concentration of 3 proteins being increased, including nucleoside diphosphate kinase and lamin-A/C, and
of 26 protein species being decreased, including ATP synthase, fatty acid binding-protein, isocitrate dehydrogenase, NADH
dehydrogenase, porin, peroxiredoxin, adenylate kinase, tropomyosin, actin, and myosin light chains. Hence, the lack of cardiac
dystrophin appears to trigger a generally perturbed protein expression pattern in the MDX heart, aﬀecting especially energy
metabolism and contractile proteins.
1.Introduction
The identiﬁcation of the gene responsible for the pri-
mary defect in X-linked muscular dystrophy [1]l e dt o
the discovery of its protein product, the large membrane
cytoskeletal element dystrophin [2]. The full-length Dp427
isoform of dystrophin is almost completely missing from
the dystrophic surface membrane [3], which triggers the
characteristic dystrophic phenotype of progressive skeletal
muscle weakness and ﬁbre wasting [4]. Mutations in the
dystrophin gene cause the most prevalent and lethal gender-
speciﬁc genetic disease of childhood, Duchenne muscular
dystrophy (DMD), and its more benign and less frequent
c o u n t e r p a r tB e c k e r ’ sm u s c u l a rd y s t r o p h y ,a sw e l la sX -
linked dilated cardiomyopathy [5]. Dystrophin forms a
supramolecular complex with various surface glycoproteins
[6] that are involved in cellular signaling, receptor clustering
and stabilization of the cellular periphery [7]. Tissue-speciﬁc
variations in dystrophin isoforms delegate the composition
and subcellular localization of the dystrophin-glycoprotein
complex, and hence the function of the speciﬁc mem-
brane assembly may vary between the brain, heart, and
skeletal muscles [8]. In muscular dystrophy, deﬁciency in
dystrophin causes a signiﬁcant reduction in the surface-
associated glycoprotein complex, which severely impairs the
integrity of the sarcolemma [9]a n dc a u s e sab r o a ds p e c t r u m
of downstream alterations such as enhanced proteolytic
destruction of muscle proteins and abnormal Ca2+-handling
[10]. This classiﬁes DMD primarily as a genetic disorder of
skeletal muscle, but pathological alterations are also present
in cardiac muscle and diaphragm, as well as the peripheral
and central nervous system [11].
The majority of DMD patients develop clinical cardiac
symptoms during the second decade of life [12], including
arrhythmias, cardiomyopathy, and regional wall abnormali-
ties, leading to fatal cardiac complications in about 20% of
cases [13]. On the cellular level, the gradual replacement of
cardiac ﬁbres by connective and fatty tissue is a hallmark2 Journal of Biomedicine and Biotechnology
of the dystrophic heart [14]. While dystrophin-deﬁcient
skeletal muscles undergo cycles of ﬁbre degeneration and
regeneration, dystrophic heart ﬁbres exhibit only a limited
regenerative capacity causing a progressive decline in the
cardiomyocyte population of the dystrophic heart [15].
Since cardiomyopathy is a frequent occurrence in inherited
muscular dystrophies [16] ,an u m b e ro fn o v e lt h e r a p e u t i c
approaches are tested to speciﬁcally address the cardiac
symptoms [17, 18], especially membrane-stabilizing agents
such as tri-block poloxamers [19]. In this study, we used
the X-linked muscular dystrophy (MDX) mouse, a well-
established animal model of DMD [20] that is missing
dystrophin isoform Dp427 [21]. Although the dystrophic
phenotype of young MDX hearts does not represent a
perfect replica of DMD-related cardiomyopathic complica-
tions [22], in aged MDX hearts the pathological changes
are of considerable clinical relevance [23–25] and cardiac
MDX ﬁbres are frequently used to evaluate new treatment
strategies to counteract cardiomyopathic complications
[26–29].
The absence of cardiac dystrophin is clearly associated
with necrotic changes, extensive inﬁltration of inﬂammatory
cells, increase in adipose tissue, interstitial ﬁbrosis, tachycar-
dia, and impaired contractile properties in the MDX heart
[22, 30, 31]. In analogy to DMD hearts, the expression of
dystrophin-associated glycoproteins is also greatly reduced
in dystrophin-deﬁcient MDX heart cells [32]. Secondary
abnormalities in cardiac ﬁbres from the MDX mouse include
the drastic reduction in key luminal Ca2+-binding proteins
[33] and abnormal stress-induced Ca2+-inﬂux into the
cytosol [34]. Interestingly, both physical exercise and aging
seem to accelerate the dystrophic process in cardiac MDX
tissue [35, 36] ,w h e r e b yar e c e n ts t u d yb yS p u r n e ye ta l .[ 37]
revealed that heart dysfunction was most prominent at 9
months of age. This makes this age group of MDX hearts a
suitable DMD model for investigating global changes in the
cardiac MDX protein complement and was therefore chosen
in this study.
The development of mass spectrometry-based pro-
teomics for the swift identiﬁcation of proteins has decisively
enhancedtheanalyticalcapabilityofcomparativebiomedical
studies[38].Inaddition,theintroductionofﬂuorescentdyes
hasdrasticallyincreasedthetotalnumberofidentiﬁabletwo-
dimensional spots, whereby ﬂuorescence diﬀerence in-gel
electrophoresis (DIGE) can be considered one of the most
advanced biomedical tools for studying two diﬀerent sets of
soluble protein complements [39]. DIGE analysis generates
highlyreproducibleﬁndingsduetogreatlyreducedgel-to-gel
variations [40]. We have therefore used this technique here
for the proteomic proﬁling of the dystrophic MDX heart.
The usefulness of proteomics for determining the biomarker
signature of animal disease models of muscular disorders has
recently been reviewed [41]. An important aspect of genetic
mouse models is that they show, due to their inbred status,
genetically much less interindividual diﬀerences than human
patients. Therefore, considerably fewer experimental repeats
are capable of producing meaningful proteomic data. With
respect to X-linked muscular dystrophy, proteomic studies
have mostly focused on MDX skeletal muscles and have
identiﬁednumerousbiomarkercandidates,suchasadenylate
kinase[42],calsequestrin[43],regucalcin[44],andthesmall
stress protein cvHsp [45]. In general, dystrophic skeletal
muscles show an extremely perturbed protein expression
pattern. Although the initial pathobiochemical consequence
of a primary genetic abnormality in dystrophin is a severe
reduction in dystrophin-associated proteins, this seems to
result in a variety of downstream alterations in various
classesofmuscleproteinsinvolvedinﬁbrecontraction,chap-
eronefunction,ionhomeostasis,cytoskeletonformationand
metabolism [41].
In contrast, relatively little is known about global alter-
ationsinthedystrophicheart.Buildingontherecentﬁndings
of a combined metabolomic and proteomic investigation
into dystrophin deﬁciency in cardiac muscle [46], this report
describes the detailed DIGE analysis of the expression levels
of ﬂuorescently-tagged dystrophic versus normal cardiac
proteins using both pH 4–7 and pH 6–11 range gels.
Following the densitometric determination of the expression
pattern of 2,509 cardiac protein spots, mass spectrometry
identiﬁed 26 proteins being decreased, including various
myosin light chains, tropomyosin, actin, adenylate kinase,
creatine kinase, vimentin, ATP synthase, fatty acid binding-
protein, isocitrate dehydrogenase, NADH dehydrogenase,
myozenin, porin, and peroxiredoxin, and 3 proteins being
increased, including lamin-A/C and nucleoside diphosphate
kinase. These ﬁndings suggest that the loss in dystrophin
causes abnormalities in cardiac metabolism, the cellular
stressresponse,thecytoskeleton,andthecontractilemachin-
ery. In the future, these results will be useful for comple-
menting studies into the molecular mechanisms of muscular
dystrophy and for evaluating the eﬀects of novel drugs,
genetic modiﬁcations, or cell-based therapies on disease
progression.
2.MaterialsandMethods
2.1. Materials. For gel electrophoretic analyses, analytical
grade chemicals and materials were purchased from Amer-
sham Biosciences/GE Healthcare, Little Chalfont, Bucking-
hamshire, UK (CyDye DIGE ﬂuor minimal dyes Cy3 and
Cy5; 24cm pH 4–7 and 18cm pH 6–11 immobilized pH gra-
dient (IPG) strips; IPG buﬀer; iodoacetamide), Biorad Lab-
oratories, Hemel-Hempstead, Hertfordshire, UK (Laemmli-
type buﬀer system; protein molecular mass markers),
National Diagnostics, Atlanta, GA, USA (ultrapure Protogel
acrylamide stock solution), Cosmo Bio Company, Tokyo,
Japan (2D silver stain II kit), and Perbio Science, Northum-
berland, UK (Coomassie Brilliant Blue G-250). Protease
inhibitors and chemiluminescence substrate were obtained
from Roche Diagnostics (Mannheim, Germany). Sequenc-
ing grade-modiﬁed trypsin was purchased from Promega
(Madison, WI, USA). Nitrocellulose transfer stacks were
from Invitrogen (Carlsbad, CA, USA). Primary antibodies
wereobtainedfromAbcamLtd.,Cambridge,UK(ab28172to
prohibitin; ab36329 to isocitrate dehydrogenase; ab14734 to
porin isoform VDAC1; ab54824 to adenylate kinase isoform
AK1; ab5432 to ATP synthase, ab16915 to cardiac fatty acidJournal of Biomedicine and Biotechnology 3
binding protein), Sigma Chemical Company, Dorset, UK
(mAb NOQ7.5.4D to slow/cardiac myosin heavy chain; pAb
to laminin), Visionbiosystems Novocastra, Newcastle upon
Tyne, UK (mAb NCL-DYS1 against the Dp427 isoform of
dystrophin), Thermo Fisher Scientiﬁc Inc., Rockford, IL,
USA (mAb Rd301 to desmin) and Santa Cruz Biotech-
nology, Santa Cruz, CA, USA (sc27992 to succinate dehy-
drogenase). All secondary antibodies were purchased from
Chemicon International (Temecula, CA, USA). For confocal
microscopy, Superfrost Plus positively-charged microscope
slides were purchased from Menzel Glaesser (Braunschweig,
Germany). Optimum cutting temperature (OCT) com-
pound was from Sakura Finetek Europe B.V (Zoeterwoude,
Netherlands) and p-phenylenediamine (PPD)-glycerol was
purchased from Citiﬂuor Ltd. (London, UK). MitoTracker
Red CMXRos dye and Alexa Fluor-conjugated secondary
antibodies were from Invitrogen Molecular Probes (Bio
Sciences Ltd., Dun Laoghaire, Ireland). The DNA binding
dye diamidino-phenylindole (DAPI) and all other chemicals
used were of analytical grade and purchased from Sigma
Chemical Company, Dorset, UK.
2.2. Dystrophic MDX Animal Model. Hearts from male 9-
month old C57 control mice and age-matched dystrophic
mdx mice were obtained through the Bioresource Unit of
NUI Maynooth and the Animal House of the University of
Bielefeld. Animals were kept under standard conditions and
all procedures were performed in accordance with German
and Irish guidelines on the use of animals for scientiﬁc
experiments. Mice were killed by cervical dislocation and
their hearts removed and snap-frozen [32]. As previously
demonstrated by immunoblotting, the MDX mouse cohort
used in this study lacks the 427kDa isoform of cardiac
dystrophin and shows a drastic reduction in dystrophin-
associated glycoproteins, such as dystroglycans and sarcogly-
cans [32, 33].
2.3. Preparation of Total Heart Muscle. For the proteomic
proﬁling of crude cardiac extracts, three normal and three
age-matched dystrophic hearts were separately prepared by
washing with distilled water to remove excess blood. Muscle
tissue was pulverized by grinding in liquid nitrogen using a
mortar and pestle. Ground hearts were solubilized in lysis
buﬀer with the ratio 100mg wet weight to 1mL lysis buﬀer
consisting of 9.5M urea, 2% CHAPS, 0.8% IPG buﬀer pH
3–10, 1% (w/v) DTT and protease inhibitors [45]. Samples
for DIGE analysis were placed in buﬀer containing only urea
and CHAPS. Samples were gently rocked for 30 minutes and
protein concentration was determined using the Bradford
assay system [47]. For immunoblot analysis samples were
placed into homogenization buﬀer (0.5M Hepes pH 7.4,
200mM EGTA, 10% (w/v) sucrose, 3mM MgCl2,a n d
0.1% (w/v) NaN3). The buﬀer was supplemented with a
protease inhibitor cocktail to prevent protein degradation
[45]. Extracts were shaken at 4◦C on a Thermomixer from
Eppendorf (Hamburg, Germany) for 4 hours and then
centrifuged at 4◦C for 20 minutes at 20,000×gi na n
Eppendorf 5417R bench centrifuge.
2.4. Diﬀerence in-Gel Electrophoretic Analysis. Potential dif-
ferences in the expression pattern of the soluble proteome
from normal and MDX cardiac muscle were analysed
usingtheﬂuorescencediﬀerencein-gelelectrophoreticDIGE
technique [39], as recommended by Karp and Lilley [48].
The ﬂuorescent dyes Cy3 and Cy5 were reconstituted as a
stock solution of 1mM in fresh dimethylformamide, then
diluted to a 0.2mM solution prior to use. Labeling was
performedwith200pmolsofCy3ﬂuordyeper25μgprotein.
An internal pooled standard of every sample was prepared
with the Cy5 ﬂuor. Labelled samples were then vortexed and
incubated for 30 minutes on ice in the dark. The reaction
was quenched with 10mM lysine on ice for 10 minutes [49].
For isoelectric focusing, pH 6–11IPG strips were rehydrated
for 12 hours in rehydration buﬀer (8M Urea, 0.5% CHAPS,
0.2% DTT, and 0.2% ampholytes) with the addition of
1.2% (v/v) DeStreak rehydration solution (Amersham Bio-
sciences/GE Healthcare, Little Chalfont, Buckinghamshire,
UK). Sample and equal volumes of reducing lysis buﬀer
(9.5M Urea, 2% CHAPS, 2% DTT, and 1.6% ampholytes)
were added by anodic cup loading. For pH 4–7 focusing, IPG
strips were in-gel rehydrated with sample and equal volumes
of reducing lysis buﬀer made up in rehydration buﬀer. The
strips were run on an Amersham IPGphor IEF system with
the following running conditions: 3500V for 21.3 hours, a
3500 to 8000V gradient over 10 minutes in, and 8000V
for 2 hours. For ﬁrst dimension separation in the pH 6–
11 range the following protocol was employed: 80V for 4
hours, 100V for 2 hours, 500V for 1.5 hours, 1000V for
1 hour, 2000V for 1 hour, 4000V for 1 hour, 6000V for 2
hours, and ﬁnally 8000V for 2.5 hours. Following isoelectric
focusing, the IPG strips were equilibrated for 20 minutes
ﬁrstly in buﬀer containing 6M urea, 30% (w/v) glycerol,
2% (w/v) SDS, 100mM Tris-HCl, pH 8.8 with the addition
of 100mM DTT and subsequently for 20 minutes in buﬀer
supplemented with 0.25M iodoacetamide [49]. Strips were
brieﬂywashedinsodiumdodecylsulfate-containingrunning
buﬀer (125mM Tris, 0.96M glycine, 0.1% (w/v) SDS) and
placed on top of 12.5% (w/v) resolving gels. To seal the strip
gels, they were overlaid with the above-described running
buﬀer containing 1% (w/v) agarose. The separation of the
cardiac proteins was carried out in the second dimension
by standard SDS polyacrylamide gel electrophoresis using
the DodecaCell system from Bio-Rad Laboratories (Hemel
Hempstead, Herts., UK). Slab gels contained 50μgp r o t e i n
per gel. Electrophoresis was carried out overnight for
approximately 18 hours in the dark at 1.5V per 21cm-gel
until the Bromophenol Blue tracking dye just ran oﬀ the
gel.
2.5. Protein Visualization and Data Analysis. Fluorescent
CyDye-labelled cardiac proteins were visualized using a
Typhoon Trio variable mode imager form Amersham Bio-
sciences/GE Healthcare (Little Chalfont, Bucks., UK). For
image acquisition, Cy5- and Cy3-labelled proteins were
scanned at a wavelength of λ = 650nm and λ =
550nm, respectively. Photomultiplier tube (PMT) values
were optimised so that the volume of the most abundant
spot was between 80,000 and 99,000 when scanned at4 Journal of Biomedicine and Biotechnology
a resolution of 100μm. This guaranteed that no spot would
be saturated on the gel, therefore interfering with accurate
analysis. The Cy3 images were then analysed using Pro-
genesis SameSpots software version 3.2.3 from NonLinear
Dynamics (Newcastle upon Tyne, UK) and normalised
against their corresponding Cy5 image. Gels were aligned
to the reference image. Following detection of spots, the
gels were placed into groups (MDX versus normal) and
analysed to determine signiﬁcant diﬀerences in 2D spot
abundance. An ANOVA score of 0.5 was required for spots
to be included in the subsequent analysis. Then principal
component analysis (PCA) was veriﬁed with changes dis-
playing power of <0.8 being removed from the analysis.
All remaining changed spots that met the signiﬁcance
criteria were visually checked on the aligned gels to ensure
feasibility and were subsequently identiﬁed by LC-MS/MS
analysis.
2.6. Mass Spectrometric Identiﬁcation of Cardiac Proteins.
Preparative gels containing 400μgo fp r o t e i n( 1 : 1M D X
to normal) were stained with the dye Ruthenium II
Bathophenanthroline Disulfonate Chelate (RuBPs) [50].
RuBPs-stained gels were scanned at a wavelength of λ =
550nm using the criteria outlined above. Prior to iden-
tiﬁcation via LC-MS/MS technology, 2D protein spots of
interest were excised using the automated Ettan spot picker
system from Amersham Biosciences (Little Chalfont, Bucks.,
UK). Spots were digested as outlined by Shevchenko et al.
[51]. Brieﬂy, gel pieces were destained before the addition
of 400ng trypsin per spot, incubated for 30 minutes at 4◦C
before being digested overnight at 37
◦C. 100μLo fe x t r a c t i o n
buﬀer (1:2v/v of 5% formic acid/acetonitrile) was added
to the peptides and incubated for 15 minutes at 37
◦C.
All supernantant was then transferred into fresh tubes and
extracts were dried down completely in a vacuum centrifuge.
Peptides were reconstituted in 12μLo f0 . 1 %f o r m i ca c i d ,
vortexed, sonicated, and the mixture was centrifuged for
20 minutes in cellulose spin ﬁlter tubes to remove any
gel particles. The remaining solution was placed into LC-
MS vials. Samples were analysed on an Agilent 6340 Ion
Trap LC mass spectrometer using electrospray ionization
(Agilent Technologies, Santa Clara, CA, USA) on a 10-
minute gradient of 5–100% acetonitrile/0.1% formic acid
with a post run of 1 minute [52]. Separation of peptides
was performed with a nanoﬂow Agilent 1200 series system,
equipped with a Zorbax 300SB C18μm, 4mm 40nl pre-
column. Mobile phases used were A: 0.1% formic acid, B:
90% acetonitrile and 0.1% formic acid. Samples (8μL) were
loaded onto the enrichment column with capillary ﬂow rate
s e ta t4 μL/min with a mix of A : B at a ratio of 19 : 1.
Elution was carried out with the nano pump ﬂow rate set
at 0.6μl/minute. Database searches were carried out using
Mascot MS/MS Ion search. Criterion for each search was
set at (i) species Mus musculus, (ii) two missed cleavages by
trypsin, (iii) variable modiﬁcation: oxidation of methioine,
(iv) ﬁxed modiﬁcation: carboxymethylation of cysteines, and
(v) mass tolerance of precursor ions ±2Da and product ions
±1Da.
2.7. Immunoblot Analysis. In order to verify changes in the
expression of select cardiac proteins, 1-D gel electrophoresis,
Coomassie staining and immunoblotting was performed as
previously described in detail [32]. Gels were transferred
to an “iblot” transfer unit from Invitrogen (Carlsbad, CA,
USA) for semi-dry blotting. Electrophoretic transfer was
carried out for 6 min. Blocking of nitrocellulose sheets was
achievedwithamilkproteinsolution(5%(w/v)fat-freemilk
powder in 0.9% (w/v) NaCl, 50mM sodium phosphate, pH
7.4) for 1 hour. Incubation with suﬃciently diluted primary
antibody was carried out overnight with gentle agitation.
Nitrocellulose sheets were washed and then incubated for
1 hour with secondary peroxidase-conjugated antibodies,
diluted in blocking solution. Immuno-decorated bands were
visualized by the enhanced chemiluminescence method
usingBMChemiluminescenceBlottingsubstratefromRoche
Diagnostics(Mannheim,Germany).Densitometricscanning
of immunoblots was performed on a Molecular Dynamics
300S computing densitometer (Sunnyvale, CA, USA) with
ImageJ (NIH, USA) and GraphPad Prism (San Diego, CA,
USA) software.
2.8. Confocal Microscopy. For the localization of nuclei,
mitochondria and select marker proteins, confocal micro-
scopy was used as previously described in detail [45].
Normal and dystrophic MDX hearts were mounted on
cyrocassettes at −20
◦C and transverse cryosections of 10μm
thickness were cut on a Shandon Cryotome (Life Sciences
International, Cheshire, UK). Unﬁxed tissue sections were
transferred to Superfrost Plus positively-charged microscopy
slides. For labeling of mitochondria, freshly cut tissue
sections were incubated with a 1 : 100 diluted solution
of MitoTracker Red Chloromethyl-X-Rosamine (CMXRos)
dye for 30 minute, brieﬂy washed in phosphate-buﬀered
saline and then immediately examined by microscopy [53].
CMXRos is a well-established lipophilic cationic ﬂuorescent
dye that is highly speciﬁc for mitochondria [54] and is
routinely used to measure mitochondrial function and
morphology in cell culture and in whole tissues [55]. For
immunoﬂuorescence microscopy, cryosections were brieﬂy
ﬁxed in ice-cold acetone for 5 minutes, followed by sub-
mersion in blocking solution (0.2% (w/v) bovine serum
albumin, 0.2% (v/v) Triton X-100, and 2.5% (v/v) goat
serum in phosphate-buﬀered saline) for 30 minute, and
then incubated with primary antibodies diluted in 0.2%
(w/v) bovine serum albumin and 0.2% (v/v) Triton X-100
in phosphate-buﬀered saline for 4 hours. Tissue sections
were washed twice for 30 minute in above solution omitting
antibodies and then labelled with secondary antibodies for
1 hour, followed by the above described washing procedure.
In order to determine the number of nuclei in normal
versus MDX hearts, cardiac tissue sections were labelled with
1μg/ml diamidino-phenylindole (DAPI) for 30 minute. One
drop of p-phenylenediamine (PPD)-glycerol was applied to
the immuno-decorated tissue sections and then coverslips
carefully placed over the sections, avoiding the introduction
of air bubbles. Fluorescent labelling patterns were visualised
with an Olympus IX81 microscope (Olympus Life and
Material Science Europe, Hamburg, Germany).Journal of Biomedicine and Biotechnology 5
3. Results
3.1. Comparative Proteomic Proﬁling of MDX Versus Normal
Heart Muscle. In contrast to non-ﬂuorescent protein dye
methodology, comparative studies using ﬂuorescent CyDyes
have an enhanced dynamic range of protein coverage [39].
DIGE analysis represents a highly accurate quantitative
technique that enables multiple protein samples to be
separated on the same two-dimensional gel. This reduces
the introduction of potential artifacts due to gel-to-gel
variations, making comparative DIGE approaches one of the
most powerful analytical tools for conducting comparative
biomedical investigations [40]. In order to determine global
changes in the heart due to deﬁciency in the dystrophin
isoform Dp427, we have carried out a DIGE analysis of
crude tissue extracts from 9-month old normal versus age-
matched dystrophic MDX mice. Due to the high cost of
breeding and maintaining mice to old age, as well as the
considerable cost of ﬂuorescent tagging of large protein
populations, the number of biological repeats and analytical
DIGE gels was kept to a minimum. In order to satisfy
the statistical requirements for the generation of proper
proteomicdatasetsandperformanoptimizedDIGEanalysis
of normal versus aﬀected proteomes, we have followed the
recommendations by Urfer et al. [56] and Karp and Lilley
[48], respectively. In the ﬁrst dimensional separation step via
isoelectricfocusing,bothapH4–7andapH6–11rangewere
employed to cover as many cardiac proteins with diﬀering
charges as possible. Figure 1 illustrates the neutral and the
more acidic range of protein species and Figure 2 shows the
separation of neutral and more basic heart proteins. Shown
are representative two-dimensional gels of Cy3-labelled nor-
malmuscle(Figure1(a);Figure2(a),Cy3-labelleddystrophic
muscle (Figure 1(c); Figure 2(c) and corresponding Cy5-
labelled pooled standards (Figures 1(b),1(d); Figures 2(b),
2(d), which were analysed with the help of a Typhoon Trio
variableimagerandProgenesis2Danalysissoftware.Overall,
2509 distinct protein species were recognized on the lower
and higher pH-range gels. Recently Raddatz et al. [57]h a v e
catalogued the soluble murine heart protein complement.
The protein spot pattern presented here agrees in large parts
with their comprehensive 2D proteomic map of cardiac
tissue. Out of 2048 detectable protein spots on the pH 4–7
gels and 487 detectable protein spots on pH 6–11 gels, 79
proteinspotsshowedadrasticdiﬀerentialexpressionpattern,
with 3 proteins being increased and 26 distinct protein
species being decreased. Electrospray ionization MS/MS
analysis was carried out to unequivocally identify the cardiac
proteins with a changed abundance in dystrophic heart
ﬁbres.
3.2. DIGE Analysis of the Dystrophin-Deﬁcient Heart. Al i s t
of the cardiac protein species with a drastically altered
expression level in dystrophic MDX tissue is shown in
Table 1. The information on the 79 DIGE-identiﬁed protein
spots combine data from both pH 4–7 and pH 6–11 gels
and contain the spot number, protein name, protein ID,
number of matched peptides, percentage sequence coverage,
the relative molecular mass, pI-value, Mascot score and
fold-change of individual proteins aﬀected by deﬁciency
in dystrophin. Since the MS-based analysis identiﬁed a
large number of matched peptide sequences, these data
are not shown. The majority of identiﬁed cardiac proteins
belonged to the main classes of metabolic or contractile
proteins. Components of the actomyosin apparatus, enzy-
matic and regulatory elements of mitochondria, glycolytic
enzymes, metabolic transporters, cellular stress proteins
and cytoskeletal components were clearly identiﬁed by MS
analysis. Cardiac proteins with a dystrophy-related change in
abundance ranged in molecular mass from apparent 14kDa
to 90kDa and covered a pI-range from approximately 5
to 9. DIGE Cy5 master gels of both the pH 4–7 and the
pH 6–11 range are shown in Figure 3(a), 3(b), so that it
is possible to correlate MS-identiﬁed protein species, listed
in Table 1, with distinct two-dimensional spots of altered
density in the dystrophic heart. An increased expression
level was shown for 3 cardiac proteins, that is, nucleoside
diphosphate kinase B (spot 1), the nuclear lamina matrix
protein lamin A/C (spot 2), and a component of the
electron-transferring ﬂavoprotein dehydrogenase (spot 3).
All other identiﬁed protein species exhibited a decreased
abundance in dystrophin-deﬁcient myocardial tissue. These
cardiac proteins are marked and numbered 4 to 79 in the
Cy5-labelled master gels of Figure 3.T h ep r o t e i ns p e c i e s
with the highest decrease in concentration was identiﬁed
as the anti-oxidant enzyme peroxiredoxin-6 (spot 79). In
addition, mitochondrial ATP synthase (spots 50, 55, 69, 72,
73, 74, 77), isocitrate dehydrogenase (spot 38, 42), NADH
dehydrogenase (spot 40), pyruvate dehydrogenase (spots 11,
14, 15, 20, 25, 34), isovaleryl-CoA dehydrogenae (spots 8,
19), dienoyl-CoA isomerase (spot 17), oxoglutarate dehy-
drogenase (spot 7), prohibitin (spot 6), electron-transferring
ﬂavoprotein (spots 5, 17), myozenin-2 (spot 4), voltage-
dependent anion-selective channel protein VDAC1 (spot
41), the slow/cardiac isoform of myosin light chain MLC2
(spots 26, 48, 62, 65, 70, 78), myosin light chain MLC3
(spots 53, 61, 76), cardiac alpha-actin (spots 21, 39, 45, 46,
56, 60, 64, 66, 67, 71, 75), alpha-1 tropomyosin (spots 35,
59), adenylate kinase AK1 (spot 68), creatine kinase (spot
16), cytochrome c oxidase (spots 22, 51), cytochrome b-
c complex (spots 10, 30, 57, 63), desmin (spot 43, 47, 52,
54, 58), vimentin (spots 12, 23), cardiac fatty acid binding-
protein FABP-3 (spots 27, 33, 49), heat shock protein Hsp27
(spot 18), heat shock protein Hsp60 (spots 31, 37, 44),
enolase (spots 13, 28, 32), DJ-1 protein (spot 29), valsolin-
containing protein VCP (spot 24), and albumin (spot 9)
were identiﬁed. The results for 2 decreased protein spots
have not been included in Table 1, since only 1 matched
peptide per cardiac protein could be determined by MS
analysis. It is international standard that proteomic studies
only list proteins with sequence coverage of less than 10%
when at least 2 separate matched peptide sequences are
available for an independent identiﬁcation. The peptide
sequences LGANSLLDLVVFGR (2% sequence coverage)
and LTFDSSFSPNTGK (4% sequence coverage) identiﬁed
the nonlisted cardiac proteins as succinate dehydrogenase
(73.6kDa; pI 7.1) and porin isoform VDAC1 (32.5kDa; pI
8.6), respectively.6 Journal of Biomedicine and Biotechnology
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Figure 1: 2D gel electrophoretic analysis of the dystrophic heart using the pH 4–7 range. Shown are Cy3-labelled gels of the soluble fraction
from normal (a) and dystrophic MDX (c) cardiac muscle, as well as Cy5-labelled gels containing pooled standards ((b), (d)). Representative
ﬂuorescent DIGE gels with electrophoretically separated proteins are shown for the pH 4–7 range. The pH-values of the ﬁrst dimension gel
system and molecular mass standards (in kDa) of the second dimension are indicated on the top and on the left of the panels, respectively.
3.3. Decreased Proteins in Dystrophic Heart Muscle. To illus-
trate representative examples of key cardiac proteins with
a drastically decreased expression in dystrophin-deﬁcient
ﬁbres, enlarged images of DIGE-identiﬁed protein spots are
shown in Figure 4. The direct comparison of ﬂuorescently
labeled 2-D protein spots, which have been unequivocally
identiﬁedbymassspectrometricanalysis(Table1),showsthe
cytosolicAK1isoformofadenylatekinase,themitochondrial
proteins ATPase synthase, porin isoform VDAC1, isocitrate
dehydrogenase, succinate dehydrogenase, and prohibitin, as
well as DJ1-protein, the stress protein Hsp60 and myosin
light chain isoform MLC2. A large proportion of the cardiac
proteins identiﬁed in this study by DIGE analysis belong to
the contractile apparatus, the cellular stress response and the
cytoskeletal network, as well as mitochondrial metabolism
includingoxidativephosphorylation,thecitricacidcycleand
fatty acid transportation.
3.4. Immunoblot Analysis of Dystrophic Heart Muscle. Pre-
vious studies have clearly shown that the deﬁciency in
dystrophin triggers a drastically reduced concentration of
the dystrophin-associated α/β-dystroglycan complex in the
MDX heart [32]. Immunoblotting has established dis-
tinct alterations down-stream of the cardiac dystrophin-
glycoprotein complex, such as the reduction in the luminal
Ca2+-binding proteins calsequestrin and sarcalumenin [33].
In analogy, we employed Western blotting here to verify
the results of our DIGE analysis by immuno-decoration
analysis of a select group of cardiac proteins. In this respect,
it is important to stress that the mass spectrometry-based
proteomic analysis of individual 2D spots identiﬁes changes
in distinct subspecies of proteins and not alterations in the
total population of a protein isoform. The recent large-
scale cataloguing of the heart proteome has shown that
cardiactissuescontainthousandsofdiﬀerentproteinspecies,
whereby many proteins are represented by a large number
of distinct 2D-spots in analytical gels [57–59]. It is one
of the great advantages of modern proteomics that this
analytical approach can diﬀerentiate between diﬀerently
charged or sized subspecies of individual proteins. Since 1D
immunoblotting or immunoﬂuorescence microscopy often
do not recognize all forms of a speciﬁc protein due toJournal of Biomedicine and Biotechnology 7
Table 1: List of DIGE-identiﬁed proteins with a changed abundance in 9-month old dystrophic MDX heart muscle.
Spot No. Protein name Protein ID Peptides
matched
Coverage
(%)
Molecular
mass (kDa)
Isoelectric
point (pI) Mascot score Fold change
1
Nucleoside
diphosphate
kinase B
NDKB MOUSE 4 34 17.5 6.9 69 4.4
2 Lamin-A/C LMNA MOUSE 4 6 74.5 6.5 111 1.9
3
Electron transfer
ﬂavoprotein-
ubiquinone
oxidoreductase,
mitochondrial
ETFD MOUSE 8 15 68.9 7.3 45 1.8
4 Myozenin-2 MYOZ2 MOUSE 4 20 29.8 8.5 145 0.67
5
Electron transfer
ﬂavoprotein subunit
alpha,
mitochondrial
ETFA MOUSE 2 12 35.3 8.6 89 0.67
6 Prohibitin PHB MOUSE 8 41 29.9 5.6 290 0.67
7
Dihydrolipoyllysine-
residue
succinyltransferase
component of
2-oxoglutarate
dehydrogenase
complex,
mitochondrial
ODO2 MOUSE 3 6 49.3 9.1 86 0.63
8
Isovaleryl-CoA
dehydrogenase,
mitochondrial
IVD MOUSE 7 23 46.7 8.5 89 0.59
9 Serum albumin ALBU MOUSE 3 5 70.7 5.8 82 0.59
10
Cytochrome b-c1
complex subunit
Rieske,
mitochondrial
UCRI MOUSE 4 13 29.6 8.9 84 0.56
11
Dihydrolipoyllysine-
residue
acetyltransferase
component of
pyruvate
dehydrogenase
complex,
mitochondrial
ODP2 MOUSE 10 20 68.5 8.8 117 0.53
12 Vimentin VIME MOUSE 11 20 53.7 5.1 118 0.53
13 Beta-enolase ENOB MOUSE 8 19 47.3 6.7 111 0.50
14
Pyruvate
dehydrogenase E1
component subunit
beta, mitochondrial
ODPB MOUSE 8 31 39.3 6.4 279 0.50
15
Pyruvate
dehydrogenase E1
component subunit
beta, mitochondrial
ODPB MOUSE 3 19 39.3 6.4 134 0.50
16 Creatine kinase
M-type KCRM MOUSE 2 4 43.3 6.6 47 0.50
17
Delta(3,5)-
Delta(2,4)-dienoyl-
CoA isomerase,
mitochondrial
ECH1 MOUSE 4 24 36.4 7.6 201 0.508 Journal of Biomedicine and Biotechnology
Table 1: Continued.
Spot No. Protein name Protein ID Peptides
matched
Coverage
(%)
Molecular
mass (kDa)
Isoelectric
point (pI) Mascot score Fold change
18 Heat shock protein
beta-1 Hsp27 HSPB1 MOUSE 2 8 23.1 6.1 50 0.50
19
Isovaleryl-CoA
dehydrogenase,
mitochondrial
IVD MOUSE 7 17 46.7 8.5 98 0.50
20
Pyruvate
dehydrogenase
protein X
component,
mitochondrial
ODPX MOUSE 5 11 54.3 7.6 63 0.48
21 Actin, alpha cardiac
muscle 1 ACTC MOUSE 6 19 42.3 5.2 104 0.48
22
Cytochrome c
oxidase subunit 5B,
mitochondrial
COX5A MOUSE 2 14 14.1 8.7 52 0.48
23 Vimentin VIME MOUSE 13 27 53.7 5.1 122 0.48
24
Transitional
endoplasmic
reticulum ATPase
(valosin-containing
protein VCP)
TERA MOUSE 5 10 89.9 5.1 171 0.46
25
Pyruvate
dehydrogenase E1
component subunit
beta, mitochondrial
ODPB MOUSE 4 14 39.3 6.4 100 0.44
26
Myosin regulatory
light chain 2,
ventricular/cardiac
muscle isoform
MLRV MOUSE 9 52 18.9 4.9 209 0.44
27
Fatty acid-binding
protein FABP-3,
heart
FABPH MOUSE 5 37 14.8 6.1 149 0.44
28 Enolase 1, alpha ENOA MOUSE 2 3 47.5 6.4 43 0.44
29 DJ-1 protein PARK7 MOUSE 4 26 20.2 6.3 90 0.44
30 Cytochrome b-c1
complex QCR1 MOUSE 6 17 53.4 5.8 83 0.44
31
60 kDa heat shock
protein, Hsp60,
mitochondrial
CH60 MOUSE 2 6 61.1 5.9 63 0.42
32 Beta-enolase ENOB MOUSE 3 7 47.3 6.7 92 0.42
33
Fatty acid binding
protein, FABP-3,
heart
FABPH MOUSE 7 52 14.8 6.1 162 0.42
34
Pyruvate
dehydrogenase
protein X
component,
mitochondrial
ODPX MOUSE 2 4 54.3 7.6 66 0.42
35 Tropomyosin
alpha-1 chain TPM1 MOUSE 15 43 32.7 4.7 302 0.40
36
Electron transfer
ﬂavoprotein subunit
alpha,
mitochondrial
ETFA MOUSE 8 33 35.3 8.6 235 0.40Journal of Biomedicine and Biotechnology 9
Table 1: Continued.
Spot No. Protein name Protein ID Peptides
matched
Coverage
(%)
Molecular
mass (kDa)
Isoelectric
point (pI) Mascot score Fold change
37
60 kDa heat shock
protein, Hsp60,
mitochondrial
CH60 MOUSE 12 32 61.1 5.9 346 0.40
38
Isocitrate
dehydrogenase
[NAD] subunit
alpha,
mitochondrial
IDH3A MOUSE 9 29 40.1 6.3 164 0.40
39 Actin, alpha cardiac
muscle 1 ACTC MOUSE 12 31 42.3 5.2 317 0.39
40
NADH
dehydrogenase
[ubiquinone]
ﬂavoprotein 2,
mitochondrial
NDUV2 MOUSE 6 29 27.6 7.0 370 0.39
41
Voltage-dependent
anion-selective
channel protein
VDAC1
VDAC1 MOUSE 10 29 32.5 8.6 292 0.39
42
Isocitrate
dehydrogenase
[NAD] subunit
alpha,
mitochondrial
IDH3A MOUSE 13 39 40.1 6.3 376 0.39
43 Desmin DESM MOUSE 30 50 53.5 5.2 1184 0.39
44
60 kDa heat shock
protein, Hsp60,
mitochondrial
CH60 MOUSE 25 38 61.1 5.9 842 0.37
45 Actin, alpha cardiac
muscle 1 ACTC MOUSE 10 26 42.3 5.2 276 0.36
46 Actin, alpha cardiac
muscle 1 ACTC MOUSE 4 14 42.3 5.2 88 0.36
47 Desmin DESM MOUSE 15 37 53.5 5.2 349 0.36
48
Myosin regulatory
light chain 2, atrial
isoform
MLRA MOUSE 9 57 19.6 4.8 299 0.36
49
Fatty acid-binding
protein, FABP-3,
heart
FABPH MOUSE 12 61 14.8 6.1 425 0.35
50
ATP synthase
subunit beta,
mitochondrial
ATPB MOUSE 18 40 56.3 5.2 1093 0.35
51 Cytochrome c
oxidase subunit 5A COX5A MOUSE 7 28 16.3 6.1 286 0.35
52 Desmin DESM MOUSE 26 62 53.5 5.2 1657 0.35
53 Myosin light chain 3 MYL3 MOUSE 6 41 22.5 5.0 90 0.35
54 Desmin DESM MOUSE 12 30 53.5 5.2 431 0.33
55
ATP synthase
subunit d,
mitochondrial
ATP5H MOUSE 3 21 18.8 5.5 48 0.33
56 Actin, alpha cardiac
muscle 1 ACTC MOUSE 16 40 42.3 5.2 598 0.32
57 Cytochrome b-c1
complex QCR1 MOUSE 12 27 53.4 5.8 330 0.3210 Journal of Biomedicine and Biotechnology
Table 1: Continued.
Spot No. Protein name Protein ID Peptides
matched
Coverage
(%)
Molecular
mass (kDa)
Isoelectric
point (pI) Mascot score Fold change
58 Desmin DESM MOUSE 36 68 53.5 5.2 1289 0.32
59 Tropomyosin
alpha-1 chain TPM1 MOUSE 21 46 32.7 4.7 605 0.32
60 Actin, alpha cardiac
muscle 1 ACTC MOUSE 18 59 42.3 5.2 450 0.31
61 Myosin light chain 3 MYL3 MOUSE 11 63 22.5 5.0 231 0.30
62
Myosin regulatory
light chain 2,
ventricular/cardiac
muscle isoform
MLRV MOUSE 13 73 18.9 4.9 118 0.29
63 Cytochrome b-c1
complex QCR1 MOUSE 12 31 53.4 5.8 342 0.29
64 Actin, alpha cardiac
muscle 1 ACTC MOUSE 7 36 42.3 5.2 160 0.29
65
Myosin regulatory
light chain 2,
ventricular/cardiac
muscle isoform
MLRV MOUSE 7 46 18.9 4.9 354 0.29
66 Actin, alpha cardiac
muscle 1 ACTC MOUSE 4 24 42.3 5.2 91 0.28
67 Actin, alpha cardiac
muscle 1 ACTC MOUSE 17 62 42.3 5.2 294 0.27
68 Adenylate kinase
isoenzyme 1 KAD1 MOUSE 5 31 21.6 5.7 174 0.26
69
ATP synthase
subunit beta,
mitochondrial
ATPB MOUSE 4 21 56.3 5.2 92 0.26
70 Myosin regulatory
light chain 2 MLRA MOUSE 6 47 19.6 4.8 168 0.25
71 Actin, alpha cardiac
muscle 1 ACTC MOUSE 18 61 42.3 5.2 302 0.25
72
ATP synthase
subunit d,
mitochondrial
ATP5H MOUSE 5 36 18.8 5.5 69 0.25
73
ATP synthase
subunit beta,
mitochondrial
ATPB MOUSE 18 51 56.3 5.2 640 0.25
74
ATP synthase
subunit beta,
mitochondrial
ATPB MOUSE 25 71 56.3 5.2 1102 0.25
75 Actin, alpha cardiac
muscle 1 ACTC MOUSE 6 16 42.3 5.2 119 0.25
76 Myosin light chain 3 MYL3 MOUSE 6 30 22.5 5.0 99 0.25
77
ATP synthase
subunit beta,
mitochondrial
ATPB MOUSE 24 70 56.3 5.2 871 0.24
78
Myosin light chain
2,
ventricular/cardiac
MLRV MOUSE 11 77 18.9 4.9 206 0.24
79 Peroxiredoxin-6 PRDX6 MOUSE 3 19 24.9 5.7 102 0.19Journal of Biomedicine and Biotechnology 11
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Figure 2:2Dgelelectrophoretic analysis ofthedystrophicheartusingthepH6–11range.ShownareCy3-labelled gels ofthesolublefraction
from normal (a) and dystrophic MDX (c) cardiac muscle, as well as Cy5-labelled gels containing pooled standards ((b), (d)). Representative
ﬂuorescent DIGE gels with electrophoretically separated proteins are shown for the pH 6–11 range. The pH-values of the ﬁrst dimension gel
system and molecular mass standards (in kDa) of the second dimension are indicated on the top and on the left of the panels, respectively.
a lack of antibody speciﬁcity, proteomic ﬁndings on an
individual 2D protein spot sometimes do not correlate
fully with the ﬁndings from biochemical or cell biological
analyses of total protein cohorts. These apparent diﬀerences
in the fate of individual subspecies of a protein versus the
total protein population probably reﬂect the complexity of
disease-related changes in the cardiac proteome. Figure 5(a)
shows a Coomassie-stained gel of crude preparations from
normal and dystrophic hearts and illustrates that no major
diﬀerences exist in the overall protein expression levels
between the two diﬀerent phenotypes. The immunoblot
analysis of laminin, desmin, the slow/cardiac myosin heavy
chain and succinate dehydrogenase revealed no major dif-
ferences in the concentration of these abundant cardiac
proteins in normal versus MDX specimens (Figures 5(b)–
5(d) and 5(g)). In contrast, immunoblotting of the enzyme
adenylate kinase AK1, the fatty acid transporter FABP3,
isocitrate dehydrogenase, ATP synthase and porin isoform
VDAC1 showed a reduced abundance in MDX preparations
(Figures 5(e), 5(f), 5(h)–5(j)). Figure 6 summarizes the
statisticalevaluationoftheimmunoblotsurveyinagraphical
presentation. The reduced expression of adenylate kinase
isoform AK1, fatty acid binding protein FABP3, isocitrate
dehydrogenase ICDH, porin isoform VDAC1, and ATP
synthase was found to be statistically signiﬁcant, while the
concentration of desmin, myosin heavy chain and succinate
dehydrogenase was shown not to be signiﬁcantly diﬀerent
between normal and dystrophic preparations. Thus the
overall isoform population of succinate dehydrogenase and
desmin does not appear to be reduced in dystrophinopathy,
although the above-described DIGE analysis showed a lower
level of distinct subspecies of these cardiac elements. In gen-
eral, the immunoblotting results support the main ﬁndings
f r o mo u rD I G Ea n a l y s i so fn o r m a lv e r s u sd y s t r o p h i ch e a r t
tissue and demonstrate independently that the deﬁciency in
dystrophinhasaprofoundeﬀectontheexpressionpatternof
the cardiac protein complement.
3.5. Immunoﬂuorescence Analysis of Dystrophic Heart Muscle.
Since the DIGE analysis of the normal versus the dystrophic12 Journal of Biomedicine and Biotechnology
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Figure 3: DIGE analysis of normal versus dystrophic MDX cardiac muscle. Shown are Cy5-labelled master gels of the soluble fraction
from mouse heart muscle, covering both the pH 4–7 (a) and pH 6–11 (b) range. Protein spots with a drastically diﬀerent expression level
are marked by circles and are numbered 1 to 79. See Table 1 for a detailed listing of cardiac muscle proteins with a changed abundance in
dystrophin-deﬁcient tissue. The pH-values of the ﬁrst dimension gel system and molecular mass standards (in kDa) of the second dimension
are indicated on the top and on the left of the panels, respectively.
MDX heart has revealed changes in a variety of mitochon-
drial components, it was important to determine whether
this alteration was due to a reduced number of mitochondria
in the dystrophic heart or internal abundance changes in
the mitochondrial protein complement. Figure 7 shows
representativeresultsfromanimmunoﬂuorescencesurveyof
mitochondrial content, nuclei and cardiac marker proteins
in dystrophic tissue. Cryosections of MDX tissue showed a
complete absence of the dystrophin isoform Dp427 (Figures
7(c), 7(d)), conﬁrming the mutant status of the dystrophic
hearts used in this study. DAPI staining revealed 229±6
and 270±18 nuclei per examined tissue section in normal
versus dystrophic tissue sections, respectively (Figures 7(a),
7(b)). The slight increase of nuclei in MDX preparations
was not statistically signiﬁcant (n = 4). Thus the proteomic
ﬁnding of a dystrophy-dependent increase in lamin-A/C is
therefore not directly related to a drastic change in the
numberofnucleipercardiactissueunit.Fluorescentlabeling
of mitochondria with the MitoTracker dye CMXRos showed
a characteristic internal staining pattern in cardiac ﬁbres
(Figures7(e)–7(h)). Fluorescent intensity values of 1470±36
and 1384 ± 4 0f o rn o r m a lv e r s u sM D Xp r e p a r a t i o n sw e r e
found not to be signiﬁcantly diﬀerent (n = 4). Hence,
lower levels of mitochondrial enzymes do not seem to be a
consequenceofadrasticdecreaseinmitochondrialdensityin
the dystrophic MDX heart. In addition, confocal microscopy
wasemployed forthe localization ofcardiacmarkerproteins.
The immunoﬂuorescence labeling of desmin (Figures 7(i)–
7(l)), prohibitin (Figures 7(m)–7(p)) and succinate dehy-
drogenase (Figures 7(q)–7(t)) was shown to be comparable
between control and pathological samples. The microscop-
ical localization of desmin and succinate dehydrogenase
revealed unexpectedly not a decrease of these proteins in
dystrophic tissue sections, as found by DIGE analysis. Hence,
although distinct subspecies of certain cardiac proteins are
aﬀected in X-linked muscular dystrophy as determined by
mass spectrometry-based proteomics, the overall isoform
complement of these elements is not drastically altered. This
indicates that no major diﬀerences exist in the expression
levels of desmin-containing intermediate ﬁlament structures
andthepopulationofcardiacmitochondriainnormalversus
dystrophin-deﬁcient cells.
4. Discussion
In order to enhance our knowledge of the molecular
pathogenesisofcardiomyopathylinkedtoX-linkedmuscular
dystrophy, a detailed proteomic proﬁling of the dystrophic
heart was carried out. The biochemical establishment of a
comprehensive disease-speciﬁc biomarker signature for X-
linked muscular dystrophy is crucial for (i) the development
of superior diagnostic methods, (ii) the identiﬁcation of
new therapeutic targets to address cellular alterations down-
stream of the primary abnormality in dystrophin, and (iii)
the evaluation of new treatment approaches to counter-
act the various pathological aspects of dystrophinopathy
[41]. The proteomic proﬁling of MDX skeletal muscle
has recently established altered expression levels of soluble
proteins involved in nucleotide metabolism, Ca2+-handling
and the cellular stress response [42–45] .T h em a s ss p e c -
trometric analysis of experimental exon skipping therapy
revealed a partial reversal of dystrophic changes in these
new signature molecules [60], illustrating the potential of
proteomic technology to decisively enhance the capabilities
of biomedical research into the molecular mechanisms that
underlie neuromuscular disorders. In contrast to skeletal
muscle, very little is known about the global pathobiochem-
ical mechanisms that lead to cardiac complications in theJournal of Biomedicine and Biotechnology 13
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Figure 4: Decreased expression of key proteins in the dystrophin-deﬁcient MDX heart. Shown are expanded views of 2-D gels of normal
versus dystrophic MDX heart tissue. Shown are the AK1 isoform of adenylate kinase, ATP synthase, DJ1-protein, fatty acid binding protein
FABP3, porin isoform VDAC1, stress protein Hsp60, isocitrate dehydrogenase (ICDH), myosin light chain MLC2, succinate dehydrogenase
(SDH) and prohibitin. The position of 2-D spots representing distinct mitochondrial proteins is indicated by arrowheads on the right.
dystrophin-deﬁcient organism. Here, we have successfully
applied the ﬂuorescent DIGE method to the large-scale
analysisofthedystrophicheart.MS-basedproteomicsclearly
revealed a drastic decrease in key metabolic, regulatory
and contractile proteins, as well as components of the
cytoskeleton and the cellular stress response. The pie chart
of Figure 8 summarizes the apparent functions of DIGE-
identiﬁed proteins with a diﬀerential expression in normal
versus dystrophin-deﬁcient heart muscle.
The DIGE analysis presented here showed a moder-
ate increase in lamin-A/C, which might improve nuclear
stability, chromatin structure and gene expression in the
dystrophic heart. Since comparative DAPI staining indicates
comparable numbers of nuclei in normal versus dystrophic
ﬁbres, tissue scarring is probably not responsible for an
increase in the number of nuclei per tissue unit. Therefore,
the elevated lamin concentration does not appear to be
associated with increased numbers of nuclei. Cardiac lamins
make up the matrix that is located close to the inner nuclear
membrane. Interestingly their deﬁciency causes familial
dilated cardiomyopathy [61]. The only drastic increase in
a cardiac protein was the 4-fold change in the expression
of nucleoside diphosphate kinase B. Nucleoside diphosphate
kinases are key regulatory enzymes involved in intracellular
di- and tri-phosphonucleoside homeostasis. Their cellular
functions are critical for signaling, proliferation, diﬀerenti-
ation and bioenergetics [62], which suggests that the up-
regulation of one of their isoforms could be considered a
countermeasureofthedystrophin-deﬁcienthearttostabilize
essential cellular functions in severely stressed muscle cells.
In contrast to the 4-fold increase in nucleoside diphosphate
kinase, our proteomic screening demonstrated a massive
decrease in a variety of cardiac proteins in the MDX
heart. The dystrophinopathy-associated loss in numerous
key proteins, which belong to diﬀerent cellular pathways
and functions in the heart, agrees with the severity of the14 Journal of Biomedicine and Biotechnology
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Figure 5: Immunoblotting survey of cardiac proteins in dystrophic tissue. Shown is a Coomassie-stained gel (a) and corresponding
immunoblots with expanded views of immuno-decorated bands ((b)–(j)). Immunoblotting was performed with antibodies to laminin
(b), desmin (c), slow/cardiac myosin heavy chain ((d); MHCs), adenylate kinase isoform AK1 (e), porin isoform VDAC1 (f), succinate
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for the statistical evaluation of this immunoblotting survey of cardiac proteins. Molecular mass standards (in kDa) are indicated on the left
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Figure 6: Graphical presentation of the immunoblot analysis of cardiac marker proteins in dystrophic tissue. Shown is the graphical
presentation of the statistical evaluation of immuno-decoration using antibodies to adenylate kinase isoform AK1 (a), fatty acid binding
protein FABP3 (b), isocitrate dehydrogenase ICDH (c), porin isoform VDAC1 (d), ATP synthase (e), desmin (f), slow/cardiac myosin heavy
chain MHCs (G) and succinate dehydrogenase SDH (H). The comparative blotting was statistically evaluated using an unpaired Student’s
t-test (n = 5; ∗P<. 05;
∗∗P<. 01). The concentration of desmin, myosin heavy chain and succinate dehydrogenase was found not to be
signiﬁcantly diﬀerent between normal and dystrophic preparations. Lanes 1 and 2 represent normal and dystrophic muscle extracts from
control and MDX mice, respectively.
cardiomyopathic complications observed in aged MDX mice
and DMD patients [13–15].
Key proteins involved in cardiac contraction, cytoskeletal
integrity, nucleotide metabolism, cellular stress response,
mitochondrial metabolism, and fatty acid transportation
were shown to be aﬀected by a deﬁciency in cardiac
dystrophin. Interestingly, Braun et al. [63] could show an
altered integration of mitochondria and ATPases in slow-
twitching MDX muscles. The coupling between mitochon-
drial creatine kinase and the adenine nucleotide translocase
systemappearstobeweakenedindystrophin-deﬁcientﬁbres.
This seems to result in a rearrangement of intracellular
energy transfer in dystrophic muscle [63]. The 6-fold
decrease in peroxiredoxin-6 may have drastic consequences
for the capability of the dystrophic heart to counter-act the
detrimental eﬀects of stressors. Peroxiredoxin-6 is a crucial
enzyme that protects cells from oxidative stress [64]. In
analogy to the reduced concentration of this antioxidant
enzyme in cardiac MDX tissue, the decrease in the small
heat shock protein Hsp27, as well as Hsp60 and DJ-1
protein, also agrees with an impaired cellular stress response
in muscular dystrophy-associated cardiomyopathy. Small
heat shock proteins provide crucial chaperone function in
striated muscles and are upregulated in the heart following
exercise training [65]. An impaired stress response could
result in the detrimental aggregation of misfolded proteins
causing cellular dysfunction in the dystrophic heart. The
dystrophinopathy-associated decrease in valsolin-containing
protein VCP might also impair cardiac function. VCP
belongs to the AAA-ATPase superfamily and is involved in
various cellular functions such as membrane fusion and cell-
cycle control, as well as protein degradation through the
ubiquitin-proteasome pathway [66].
The DIGE analysis of the MDX heart presented here has
clearly shown a severely altered concentration of numerous
key players involved in cardiac contraction and cytoskeletal
organization. In contrast to comparable levels of myosin
heavy chain, other critical contractile proteins are aﬀected
by the lack of dystrophin. The biomolecules that form
the thick and thin ﬁlaments of the basic contractile units
exist in a complex arrangement of myosin heavy chains,
myosin light chains, and actins. Muscle myosin consists
of a hexameric arrangement that is formed by two heavy
chains and two pairs of myosin light chains. Changes in
myosin light chains have been implicated in severe cardiac
impairments, such as familial hypertrophic cardiomyopathy
[67]. Hence, the reduction in the cardiac isoform of myosin
light chain MLC2, myosin light chain MLC3, and cardiac16 Journal of Biomedicine and Biotechnology
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Figure 7: Immunoﬂuorescence survey of mitochondrial content, nuclei and cardiac marker proteins in dystrophic tissue. Confocal
microscopy was used for the localization of nuclei, mitochondria and cellular markers in normal ((a), (c), (e), (g), (i), (k), (m), (o), (q),
(s)) versus dystrophic MDX ((b), (d), (f), (h), (j), (l), (n), (p), (r), (t)) heart cryosections. Shown is labeling of nuclei with the DNA binding
dye DAPI ((a), (b)), visualization of mitochondria with the red-ﬂuorescent MitoTracker dye CMXRos ((e)-(h)), and antibody labeling of
full-length dystrophin isoform Dp427 ((c), (d)), desmin DES ((i)-(l)), prohibitin PRO ((m)-(p)) and succinate dehydrogenase SDH ((q)-
(t)). The number of nuclei and the labeling of mitochondria with the MitoTracker dye CMXRos were found not to be signiﬁcantly diﬀerent
between normal and dystrophic preparations. The bars in panels (a) to (t) equal 30μm.
alpha-actin might have a severe impact on the contractile
apparatus in the dystrophic heart. Contractile weakness
observed in dystrophinopathy could be directly related to
the altered concentration of myosin light chains and actin.
C a r d i a cm u s c l ec e l l sa r ea c t i v a t e db yC a 2+-binding to TnC-
subunit of troponin and is regulated by the interactions of
tropomyosin and troponin in the thin ﬁlament. Thus, the
observed reduction of alpha-1 tropomyosin in the MDX
heart might also be of pathophysiological signiﬁcance. Since
the molecular coupling between the myosin head structure
and actin ﬁlaments, in the presence of ATP, represents
the major step that underlies the sliding of thin ﬁlaments
past thick ﬁlaments, abnormal concentrations of regulatory
proteins may result in impaired patterns of sarcomeric
shortening.
In addition, a close connection exists between the con-
tractile apparatus, the membrane-associated actin network
and the cytoskeleton. Intermediate ﬁlaments are of crucial
importance for the mechanical integrity and elasticity of
contractile ﬁbres. Although proteomics showed that the
expression levels of distinct subspecies of desmin were
reduced in dystrophic preparations, confocal microscopyJournal of Biomedicine and Biotechnology 17
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Figure 8: Overview of biological functions of DIGE-identiﬁed proteins with an altered expression in dystrophic heart muscle. The pie
chart summarizes the apparent functions of DIGE-identiﬁed proteins with a diﬀerential expression in normal versus dystrophin-deﬁcient
MDX heart muscle. A large proportion of these aﬀected proteins belong to cardiac mitochondria including metabolic elements of oxidate
phosphorylation, the citric acid cycle and fatty acid transportation, as well as proteins associated with the contractile apparatus, the cellular
stress response, and the cytoskeletal network.
and immunoblotting revealed that the overall population
of desmin isoforms is comparable between normal and
MDX heart. However, the deﬁciency in cardiac dystrophin
appears to trigger a concomitant reduction in the density
of myozenin-2 and vimentin. Myozenin-2 belongs to the
calsarcin family of proteins, a new type of sarcomeric
calcineurin-binding protein [68]. Vimentin is a crucial
intermediary ﬁlament protein and plays a key role in
cytoskeletal network formation. The abnormal expression
levels of these proteins might therefore cause disturbed
interﬁlament interactions and impaired cystoskeletal arrays,
thereby causing cellular instability in the dystrophic heart.
One of the most important ﬁndings of this mass
spectrometry-based proteomic study is the drastically
reduced concentration of numerous mitochondrial proteins
and metabolic transporters. Since mitochondria represent
the primary site for energy generation via oxidative phos-
phorylation [69], a reduction in elements belonging to the
oxidative phosphorylation complexes, the citric acid cycle
and ion homeostasis will have a profound inﬂuence on
the bioenergetic status of the dystrophic heart. Cardiac
mitochondria are involved in intermediary metabolism, cell
cycle progression, calcium signaling and the regulation of
apoptosis, as well as the production of heme and iron-sulfur
clusters. Proteomic investigations suggest that approximately
1,500 diﬀerent mitochondrial proteins exist [70]. Previous
studies have shown that altered expression levels within the
mitochondrial proteome inﬂuence many aspects of normal
development, diseases and the aging process. With respect to
the heart, mitochondrial dysfunction appears to be associ-
atedwithnumerouspathologiessuchascongestiveheartfail-
ure, ischaemia reperfusion injury and cardiomyopathy [71].
Therefore, the reduced expression of many mitochondrial
proteins associated with the matrix, outer membrane and
inner membrane system suggests an impaired metabolism
in the dystrophic heart. Reduced expression levels within
the mitochondrial proteome appear to aﬀect the functioning
of the mitochondrial ATP synthase, isocitrate dehydroge-
nase, NADH dehydrogenase, oxoglutarate dehydrogenase,
isovaleryl-CoAdehydrogenase,cytochromecoxidaseandthe
cytochrome b-c complex, all critical elements involved in
mitochondrial function in the heart [69]. This agrees with a
previousstudybyZhangetal.[72],whoreportedadecreased
citratesynthaseactivityintheMDXheart.Althoughacertain
degree of cellular scarring and the inﬁltration of fatty and
connectivetissuemayreducethenumberofcontractileﬁbres
inthedystrophicheart,aspreviouslyshownbyhistochemical
analysis [72], this does not appear to drastically alter the
density of muscle-associated mitochondria. The confocal
microscopy analysis shown in this report suggests no major
changesinthenumberofmitochondria betweennormaland
dystrophic heart muscle tissue, as judged by labeling with
the established chloromethyl-X-rosamine MitoTracker dye
which is concentrated inside mitochondria by their negative
membrane potential [53–55].
Our DIGE analysis revealed that individual protein
spots representing electron-transferring ﬂavoprotein showed
both increased and decreased abundance. Electron transfer
ﬂavoprotein ubiquinone oxidoreductase provides a crucial
link between electrons derived from fatty acid oxidation and
certain amino acids to the main respiratory chain system of
mitochondria [73]. The diﬀerential eﬀect on diﬀerent iso-
forms of this protein is diﬃcult to interpret, but dystrophin
deﬁciency must aﬀect distinct subspecies of this metabolic
element with diﬀering post-translational modiﬁcations in a
dissimilar way. The observed reduction in the rate-limiting
enzyme pyruvate dehydrogenase could have severe impact
on the utilization of energy carriers and thereby impair the
overall bioenergetics of the MDX heart. Isoforms of cardiac
prohibitin are present in the inner mitochondrial membrane
and are responsible for the eﬃcient assembly of mitochon-
drial respiratory chain enzymes and perform chaperone18 Journal of Biomedicine and Biotechnology
activity. Interestingly, a proteomic survey of mitochondrial
proteins in cardiomyocytes from chronic stressed rats has
shown a drastic increase in prohibitin [74]. Although the
overall complement of prohibitin isoforms is not drastically
aﬀected in muscular dystrophy, a reduced expression of
distinct subspecies of prohibitin in the dystrophic heart
mightbeassociatedwithanimpairedcellularstressresponse.
The only aﬀected glycolytic enzyme appears to be enolase,
indicating that mitochondrial metabolism is more severely
aﬀectedthanglycolysisindystrophy-relatedcardiomyopathy.
Interestingly, the abundance of the extracellular and intra-
cellular fatty acid transporters albumin and FABP-3, which
are considered limiting factors of oxidative metabolism in
striated muscles, is decreased in the dystrophin-deﬁcient
heart. Thus, dystrophic heart cells would be starved of
essential fuel supplies, which might trigger a decline in
contractile strength. A mitochondrial receptor present in the
outer mitochondrial membrane was identiﬁed as a porin
isoform that forms voltage-dependent anion channels. These
ion channels belong to a family of pore-forming proteins
that provide large membrane-spanning aqueous channels
[75]. The decreased concentration in the porin transport
protein would indicate a dystrophy-associated decrease in
mitochondrial function and abnormal ion homeostasis.
In contrast to a recent combined metabolomic and
proteomic study of the MDX heart [46], and in agreement
with two comprehensive proteomic studies on MDX skeletal
muscle [42, 45], we could show here a decreased abundance
of the AK1 isoform of adenylate kinase. The proteomic ﬁnd-
ing was clearly veriﬁed by immunoblot analysis. Nucleotide
metabolism, involving adenylate kinase and creatine kinase
appears to be disturbed in the dystrophic MDX heart, and
this ﬁnding might be useful for the future development
of a comprehensive biomarker signature of cardiomyopathy
associated with muscular dystrophy. Overall, our DIGE-
based screening of the soluble proteome from dystrophic
MDX hearts has revealed a severely perturbed protein
expression pattern due to deﬁciency in dystrophin. The
observed changes in essential proteins involved in cardiac
contraction, mitochondrial metabolism, the cellular stress
response and nucleotide metabolism might be useful for the
future improvement of diﬀerential diagnostic procedures,
the assessment of cardiac disease progression in X-linked
muscular dystrophies, the identiﬁcation of novel therapeutic
targets to treat cardiomopathic complications in Duchenne
muscular dystrophy, and the evaluation of novel treatment
strategies to counter-act the loss in cardiac dystrophin.
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